Global Pharmaceutical Asset Performance Management (APM) Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01251055

Publication Date:

January 20, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Pharmaceutical Asset Performance Management (APM) market size is predicted to grow from US$ 118 million in 2025 to US$ 163 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031.
Asset performance management (APM) is a proven approach to reduce unplanned downtime, decrease maintenance costs, and reduce EH&S risks.
Global Pharmaceutical Asset Performance Management (APM) key players include GE (U.S.), AVEVA Group plc (U.K.), AspenTech (U.S.), Rockwell Software (U.S.), SAP (Germany), etc. Global top five manufacturers hold a share over 65%.
North America is the largest market, with a share about 50%, followed by Europe and China, both have a share about 35 percent.
In terms of product, APM Integrity is the largest segment, with a share over 45%.
The 鈥淧harmaceutical Asset Performance Management (APM) Industry Forecast鈥� looks at past sales and reviews total world Pharmaceutical Asset Performance Management (APM) sales in 2024, providing a comprehensive analysis by region and market sector of projected Pharmaceutical Asset Performance Management (APM) sales for 2025 through 2031. With Pharmaceutical Asset Performance Management (APM) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical Asset Performance Management (APM) industry.
This Insight Report provides a comprehensive analysis of the global Pharmaceutical Asset Performance Management (APM) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Pharmaceutical Asset Performance Management (APM) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Pharmaceutical Asset Performance Management (APM) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical Asset Performance Management (APM) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical Asset Performance Management (APM).
This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical Asset Performance Management (APM) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Asset Integrity Management
Asset Reliability Management
Other
Segmentation by Application:
Large Enterprises
SMEs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GE (US)
Rockwell Software (US)
AVEVA Group plc (UK)
Bentley Systems (US)
AspenTech (US)
Nexus Global (US)
SAP (Germany)

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pharmaceutical Asset Performance Management (APM) Market Size (2020-2031)
2.1.2 Pharmaceutical Asset Performance Management (APM) Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Pharmaceutical Asset Performance Management (APM) by Country/Region (2020, 2024 & 2031)
2.2 Pharmaceutical Asset Performance Management (APM) Segment by Type
2.2.1 Asset Integrity Management
2.2.2 Asset Reliability Management
2.2.3 Other
2.3 Pharmaceutical Asset Performance Management (APM) Market Size by Type
2.3.1 Pharmaceutical Asset Performance Management (APM) Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Pharmaceutical Asset Performance Management (APM) Market Size Market Share by Type (2020-2025)
2.4 Pharmaceutical Asset Performance Management (APM) Segment by Application
2.4.1 Large Enterprises
2.4.2 SMEs
2.5 Pharmaceutical Asset Performance Management (APM) Market Size by Application
2.5.1 Pharmaceutical Asset Performance Management (APM) Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Pharmaceutical Asset Performance Management (APM) Market Size Market Share by Application (2020-2025)
3 Pharmaceutical Asset Performance Management (APM) Market Size by Player
3.1 Pharmaceutical Asset Performance Management (APM) Market Size Market Share by Player
3.1.1 Global Pharmaceutical Asset Performance Management (APM) Revenue by Player (2020-2025)
3.1.2 Global Pharmaceutical Asset Performance Management (APM) Revenue Market Share by Player (2020-2025)
3.2 Global Pharmaceutical Asset Performance Management (APM) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Pharmaceutical Asset Performance Management (APM) by Region
4.1 Pharmaceutical Asset Performance Management (APM) Market Size by Region (2020-2025)
4.2 Global Pharmaceutical Asset Performance Management (APM) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pharmaceutical Asset Performance Management (APM) Market Size Growth (2020-2025)
4.4 APAC Pharmaceutical Asset Performance Management (APM) Market Size Growth (2020-2025)
4.5 Europe Pharmaceutical Asset Performance Management (APM) Market Size Growth (2020-2025)
4.6 Middle East & Africa Pharmaceutical Asset Performance Management (APM) Market Size Growth (2020-2025)
5 Americas
5.1 Americas Pharmaceutical Asset Performance Management (APM) Market Size by Country (2020-2025)
5.2 Americas Pharmaceutical Asset Performance Management (APM) Market Size by Type (2020-2025)
5.3 Americas Pharmaceutical Asset Performance Management (APM) Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pharmaceutical Asset Performance Management (APM) Market Size by Region (2020-2025)
6.2 APAC Pharmaceutical Asset Performance Management (APM) Market Size by Type (2020-2025)
6.3 APAC Pharmaceutical Asset Performance Management (APM) Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Pharmaceutical Asset Performance Management (APM) Market Size by Country (2020-2025)
7.2 Europe Pharmaceutical Asset Performance Management (APM) Market Size by Type (2020-2025)
7.3 Europe Pharmaceutical Asset Performance Management (APM) Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pharmaceutical Asset Performance Management (APM) by Region (2020-2025)
8.2 Middle East & Africa Pharmaceutical Asset Performance Management (APM) Market Size by Type (2020-2025)
8.3 Middle East & Africa Pharmaceutical Asset Performance Management (APM) Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Pharmaceutical Asset Performance Management (APM) Market Forecast
10.1 Global Pharmaceutical Asset Performance Management (APM) Forecast by Region (2026-2031)
10.1.1 Global Pharmaceutical Asset Performance Management (APM) Forecast by Region (2026-2031)
10.1.2 Americas Pharmaceutical Asset Performance Management (APM) Forecast
10.1.3 APAC Pharmaceutical Asset Performance Management (APM) Forecast
10.1.4 Europe Pharmaceutical Asset Performance Management (APM) Forecast
10.1.5 Middle East & Africa Pharmaceutical Asset Performance Management (APM) Forecast
10.2 Americas Pharmaceutical Asset Performance Management (APM) Forecast by Country (2026-2031)
10.2.1 United States Market Pharmaceutical Asset Performance Management (APM) Forecast
10.2.2 Canada Market Pharmaceutical Asset Performance Management (APM) Forecast
10.2.3 Mexico Market Pharmaceutical Asset Performance Management (APM) Forecast
10.2.4 Brazil Market Pharmaceutical Asset Performance Management (APM) Forecast
10.3 APAC Pharmaceutical Asset Performance Management (APM) Forecast by Region (2026-2031)
10.3.1 China Pharmaceutical Asset Performance Management (APM) Market Forecast
10.3.2 Japan Market Pharmaceutical Asset Performance Management (APM) Forecast
10.3.3 Korea Market Pharmaceutical Asset Performance Management (APM) Forecast
10.3.4 Southeast Asia Market Pharmaceutical Asset Performance Management (APM) Forecast
10.3.5 India Market Pharmaceutical Asset Performance Management (APM) Forecast
10.3.6 Australia Market Pharmaceutical Asset Performance Management (APM) Forecast
10.4 Europe Pharmaceutical Asset Performance Management (APM) Forecast by Country (2026-2031)
10.4.1 Germany Market Pharmaceutical Asset Performance Management (APM) Forecast
10.4.2 France Market Pharmaceutical Asset Performance Management (APM) Forecast
10.4.3 UK Market Pharmaceutical Asset Performance Management (APM) Forecast
10.4.4 Italy Market Pharmaceutical Asset Performance Management (APM) Forecast
10.4.5 Russia Market Pharmaceutical Asset Performance Management (APM) Forecast
10.5 Middle East & Africa Pharmaceutical Asset Performance Management (APM) Forecast by Region (2026-2031)
10.5.1 Egypt Market Pharmaceutical Asset Performance Management (APM) Forecast
10.5.2 South Africa Market Pharmaceutical Asset Performance Management (APM) Forecast
10.5.3 Israel Market Pharmaceutical Asset Performance Management (APM) Forecast
10.5.4 Turkey Market Pharmaceutical Asset Performance Management (APM) Forecast
10.6 Global Pharmaceutical Asset Performance Management (APM) Forecast by Type (2026-2031)
10.7 Global Pharmaceutical Asset Performance Management (APM) Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Pharmaceutical Asset Performance Management (APM) Forecast
11 Key Players Analysis
11.1 GE (US)
11.1.1 GE (US) Company Information
11.1.2 GE (US) Pharmaceutical Asset Performance Management (APM) Product Offered
11.1.3 GE (US) Pharmaceutical Asset Performance Management (APM) Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 GE (US) Main Business Overview
11.1.5 GE (US) Latest Developments
11.2 Rockwell Software (US)
11.2.1 Rockwell Software (US) Company Information
11.2.2 Rockwell Software (US) Pharmaceutical Asset Performance Management (APM) Product Offered
11.2.3 Rockwell Software (US) Pharmaceutical Asset Performance Management (APM) Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Rockwell Software (US) Main Business Overview
11.2.5 Rockwell Software (US) Latest Developments
11.3 AVEVA Group plc (UK)
11.3.1 AVEVA Group plc (UK) Company Information
11.3.2 AVEVA Group plc (UK) Pharmaceutical Asset Performance Management (APM) Product Offered
11.3.3 AVEVA Group plc (UK) Pharmaceutical Asset Performance Management (APM) Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 AVEVA Group plc (UK) Main Business Overview
11.3.5 AVEVA Group plc (UK) Latest Developments
11.4 Bentley Systems (US)
11.4.1 Bentley Systems (US) Company Information
11.4.2 Bentley Systems (US) Pharmaceutical Asset Performance Management (APM) Product Offered
11.4.3 Bentley Systems (US) Pharmaceutical Asset Performance Management (APM) Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Bentley Systems (US) Main Business Overview
11.4.5 Bentley Systems (US) Latest Developments
11.5 AspenTech (US)
11.5.1 AspenTech (US) Company Information
11.5.2 AspenTech (US) Pharmaceutical Asset Performance Management (APM) Product Offered
11.5.3 AspenTech (US) Pharmaceutical Asset Performance Management (APM) Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 AspenTech (US) Main Business Overview
11.5.5 AspenTech (US) Latest Developments
11.6 Nexus Global (US)
11.6.1 Nexus Global (US) Company Information
11.6.2 Nexus Global (US) Pharmaceutical Asset Performance Management (APM) Product Offered
11.6.3 Nexus Global (US) Pharmaceutical Asset Performance Management (APM) Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Nexus Global (US) Main Business Overview
11.6.5 Nexus Global (US) Latest Developments
11.7 SAP (Germany)
11.7.1 SAP (Germany) Company Information
11.7.2 SAP (Germany) Pharmaceutical Asset Performance Management (APM) Product Offered
11.7.3 SAP (Germany) Pharmaceutical Asset Performance Management (APM) Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 SAP (Germany) Main Business Overview
11.7.5 SAP (Germany) Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂